Frederic M Enright

Title: Frederic M Enright: Innovator in Eucaryotic Pathogen Inhibition

Introduction

Frederic M Enright is a notable inventor based in Baton Rouge, Louisiana. He has made significant contributions to the field of biomedical research, particularly in the inhibition of eucaryotic pathogens and the stimulation of lymphocytes and fibroblasts.

Latest Patents

Enright holds two patents that focus on the use of lytic peptides, such as cecropins and sarcotoxins, to inhibit eucaryotic pathogens and neoplasms. His latest patents detail methods for contacting eucaryotic cells with these peptides, either alone or in combination with lysozyme, to effectively lyse or inhibit target cells. These target cells include eucaryotic microorganisms, such as protozoa, as well as mammalian lymphomas and leukemias. Additionally, his patents disclose methods for stimulating the proliferation of lymphocytes and fibroblasts, which can be applied in both in vitro and in vivo settings.

Career Highlights

Enright's work at Helix Biomedix Inc. has positioned him as a key figure in the development of innovative therapeutic strategies. His research has the potential to impact the treatment of various diseases caused by intracellular pathogens, including viruses and bacteria.

Collaborations

He has collaborated with notable colleagues, including Jesse M Jaynes and Kenneth L White, to advance his research and patent applications.

Conclusion

Frederic M Enright's contributions to the field of biomedical research through his patents and work at Helix Biomedix Inc. highlight his role as an innovator in the fight against eucaryotic pathogens. His research continues to pave the way for new therapeutic approaches.